Paratek Pharmaceuticals, Inc.

148 articles with Paratek Pharmaceuticals, Inc.

• Paratek Pharmaceuticals to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference

  1/6/2021

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference

• Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan from R-Bridge Healthcare Investment Advisory, Ltd., an affiliate of CBC GroupProceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc.

  1/4/2021

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced the Company entered into a $60 million non-recourse loan agreement with an affiliate of R-Bridge Healthcare Investment Advisory (the R-Bridge Loan) that will be repa

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Dec 01, 2020

  12/1/2020

  Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announced that on November 30, 2020, the Company granted stock options and restricted stock units to one new employee of the Company.

• Paratek Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference

  11/12/2020

  Paratek Pharmaceuticals, Inc. announced that the Company will present at the 2020 Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 11:25 a.m. ET or 4:25 p.m. GMT.

• Paratek Pharmaceuticals Announces Third Quarter 2020 Total Revenue of $13.7 Million

  11/5/2020

  NUZYRA® (omadacycline) Generated Net Product Revenue of $10.9 Million in the Third Quarter 2020; a 35% Increase Over the Prior Quarter

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Nov 02, 2020

  11/2/2020

  Paratek Pharmaceuticals, Inc. announced that on October 30, 2020, the Company granted stock options and restricted stock units to two new employees of the Company.

• Paratek Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 5, 2020

  10/27/2020

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m.

• Paratek Pharmaceuticals Presenting New Data on NUZYRA® (Omadacycline) at IDWeek 2020Key Highlights Include Data on NUZYRA

  10/21/2020

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, announced today that data from its NUZYRA (omadacycline) clinical and microbiology programs are being presented at the IDWeek 2020 virtual meeting. NUZYRA is a once-daily oral and

• Paratek Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference

  9/9/2020

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at H.C. Wainwright 22nd Annual Global Investment Conference,

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Sep 01, 2020

  9/1/2020

  Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, announced that on August 31, 2020, the Company granted stock options and restricted stock units to two new employees of the Company.

• Paratek Pharmaceuticals Announces Second Quarter 2020 Total Revenue of $9.3 Million including NUZYRA® (omadacycline) Net Revenue of $8.1 Million

  8/10/2020

  -- Paratek Raises Full Year 2020 Revenue Guidance; Total   Revenue guidance expected to be Between $78  and $83 Million Driven by Strong NUZYRA Net Revenue -- Company Lowering 2020 R&D and SG&A Expense Guidance to approximately $135 million Driven by Continued Focus on Operational Efficiencies -- FDA Pre-EUA Review Remains Ongoing; NUZYRA Procurement by BARDA for the Strategic National Stockpile Anticipated by year-end 2020 -- Company Strengthens Long-term

• Paratek Pharmaceuticals to Present at Two August 2020 Healthcare Conferences

  8/5/2020

  Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, announced that the Company will present at two upcoming healthcare conferences.

• Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Aug 03, 2020

  8/3/2020

  Paratek Pharmaceuticals, Inc. announced that on July 31, 2020, the Company granted stock options and restricted stock units to three new employees of the Company.

• Paratek Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10, 2020

  7/28/2020

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at 8:30 a.m.

• Paratek Pharmaceuticals Announces Change to Time of 2020 Annual Meeting of Stockholders

  5/29/2020

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced its virtual 2020 Annual Meeting of Stockholders (the “Annual Meeting”) will now be held at 9:00 a.m. Eastern Time. The previously announced date of the Annual Meeti

• Paratek Pharmaceuticals to Present at Jefferies 2020 Virtual Healthcare Conference

  5/28/2020

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at the Jefferies 2020 Virtual Healthcare Conference, Wednesday, June 3, 2020 at 8:00 a.m. ET. To access the live webcast of Paratek's

• Paratek Pharmaceuticals to Present at Bank of America Securities 2020 Health Care Conference

  5/11/2020

  Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, announced that the Company will present at Bank of America Securities 2020 Health Care Conference, Wednesday, May 13, 2020 at 11:40 a.m. ET.

• Paratek Pharmaceuticals Announces First Quarter 2020 Total Revenues of $7.9 Million including NUZYRA® (omadacycline) Net Sales of $7.3 Million

  5/11/2020

  Announced Initiation of Funding from BARDA for All FDA Required Post-Marketing Studies and Security Requirements and U.S.

• Paratek Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11, 2020

  4/30/2020

  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced the Company will host a conference call and live audio webcast on Monday, May 11, 2020 at 8:30 a.m. EDT to report its financial results for the quarter ended March

• Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for All FDA Required Post-marketing Studies for NUZYRA• (omadacycline)-- BARDA award projected to total approximately $77 million

  4/2/2020

  Paratek Pharmaceuticals, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA) has initiated funding to support all of the U.S. Food and Drug Administration (FDA) post-mar